Poster Session One: Posters #100-#190 including oral abstracts.
Enhancing CAR-NK Potency and Persistence with MyD88/CD40 Costimulation (#100)
4:45 PM
Augmentation of NK cell persistence and anti-tumor immunity by expression of a chimeric MPL/IL2RB fusion protein (#101)
4:45 PM
Accurate prediction of the strength of interaction of polymorphic NK cell receptors with MHC class I ligands modulated by peptides using protein language models (#102)
4:45 PM
Multiomic single-cell sequencing of influenza-stimulated NK cells reveals an age-, sex- and KIR-specific combination for reactivity (#103)
4:45 PM
Enrichment of CD151-expressing NK cells correlates with COVID-19 disease severity (#104)
4:45 PM
Eomesodermin defines uterine natural killer cells crucial for murine reproductive success (#105)
4:45 PM
Varying potency of self and cancer peptides in KIR3DL1 recognition of HLA-A*24:02 (#106)
4:45 PM
Single-cell transcriptional profiling reveals novel drivers of anti-cancer immunity in natural killer cells (#107)
4:45 PM
NK Cell Tailored CAR Engineering Improves Antitumor Efficacy (#108)
4:45 PM
DnaJC15-mediated regulation of metabolic resilience in NK cells (#109)
4:45 PM
Adaptations of human lung NK cells to an intratumoral environment (#110)
4:45 PM
NK CELL STIMULATION OVERCOMES CASTRATION RESISTANCE OF PROSTATE TUMORS (#111)
4:45 PM
TNFSF9-TNFRSF9 interaction is critical for EBV-transformed B cells to induce NK cell proliferation. (#112)
4:45 PM
Optimization of CAR-NK cell transduction and expansion under GMP conditions for clinical studies. (#113)
4:45 PM
Depletion of Natural Killer Cells Enhances Wound Healing in Diabetic Mice (#114)
4:45 PM
Transcriptional Insights into KIR-educated NK cells (#115)
4:45 PM
Rapid CAR Screening Platform for Optimizing NK Cell Therapy (#116)
4:45 PM
NK secretome: A Novel Strategy to Enhance NK cell Tumor-Homing and Anti-Tumor Functions (#117)
4:45 PM
Triple negative breast cancer-derived extracellular vesicle glycans impact natural killer cell functions (#118)
4:45 PM
A Uterine Microenvironment Deficient in NKG2A Programmes Cardiac Dysfunction in Adult Offspring in Mice (#119)
4:45 PM
Modeling the effects of the gut microbiota of undernourished women with Environmental Enteric Dysfunction (EED) on uterine NK cells at the maternal-fetal interface (#120)
4:45 PM
A Tri-specific killer engager (TriKE) utilizing the extracellular domain 1 of human CD4 drives NK killing of HIV-Env expressing cells and mediates strong NK activation in Rhesus Macaques (#121)
4:45 PM
Bone marrow stromal cells hamper leukemia cell induced NK cell activation and cytotoxicity (#122)
4:45 PM
Determinants of NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in SARS-CoV-2 Antibodies (#123)
4:45 PM
Co-expanding NK cells and CAR T cells for an enhanced combination therapy (#124)
4:45 PM
Longitudinal study of Natural killer cell cytotoxicity function in Australian Veterans with Gulf war illness (#125)
4:45 PM
Transient Receptor Potential Melastatin 3 and Natural Killer Cells in Myalgic Encephalomyelitis (#126)
4:45 PM
Natural Killer Cells in Myalgic Encephalomyelitis: The evolution of research into a biomarker. (#127)
4:45 PM
Immunometabolite L-2-hydroxyglutarate in Natural Killer Cell Antiviral Immunity (#128)
4:45 PM
Diminished Defenders: CD56neg NK cells retain low rituximab-mediated antibody dependent cell cytotoxicity against EBV associated Burkitt lymphoma (#129)
4:45 PM
Expansion of primary adult NK cells using a hypotonic medium treated feeder cell suspension under good manufacturing practice (#130)
4:45 PM
Natural Killer cells armed with engineered anti-Her2 antibody or Her2-CAR-NK cells show enhanced cytotoxicity over naked NK cells against Her2-overexpressing breast cancer (#131)
4:45 PM
Structural insight into A viral immunoevasin targeting the killer cell immunoglobulin-like receptor family (#132)
4:45 PM
JunB is Required for Innate and Adaptive Memory Formation During Infection (#133)
4:45 PM
Trastuzumab-induced Cardiotoxicity involves Antibody Dependent Cell Cytotoxicity (ADCC) (#134)
4:45 PM
Targeting NKG2DLs with an ADCC enhanced fusion protein for induction of NK cell reactivity against ovarian cancer (#135)
4:45 PM
Rheostat markers in natural killer cell education: Probing natural killer cell heterogeneity (#136)
4:45 PM
Cellytics NK: A novel platform for efficient and precise NK cell activity evaluation (#137)
4:45 PM
Primary Triple-negative Breast Tumours Induce Functional Impairment of Peripheral NK Cells (#138)
4:45 PM
Identification of NK subsets that exhibit enhanced ADCC against HIV-infected cells (#139)
4:45 PM
Mass Cytometry and Functional Analysis of NK cells on CTN-1101 Trial to Determine the Impact of Graft Source on Immune Reconstitution With Focus on Relapse Protection and Overall Survival (#140)
4:45 PM
Donor Selection for Allogeneic Immunotherapy Using High-Throughput Screening of HSC-derived Natural Killer Cells (#141)
4:45 PM
Functional characterization of expanded HSC-derived NK cells, an optimal source for allogeneic cell therapy (#142)
4:45 PM
Tissue-resident NK Cell Metabolism and Function in the Human Lung (#143)
4:45 PM
MEK inhibition restores development and anti-leukemic function of NK cells in AML (#144)
4:45 PM
Optimizing NK cell expansion with K562-mbIL-18/-21 feeder cells and ensuring feeder cell-free NK products (#145)
4:45 PM
Uncovering NK Cell Heterogeneity with MSparkles: A New Platform for Advanced Single-Cell Cytotoxicity Analysis (#146)
4:45 PM
The role of intracellular Ca2+ signaling for CAR-NK cell killing efficiency in NK cells (#147)
4:45 PM
Understanding the molecular basis of immune heterogeneity in NK cells during controlled infection with P. falciparum (#148)
4:45 PM
Enhanced Anti-Myeloma Efficacy of BCMA-CAR and Armored BCMA-IL15-CAR NK Cells against Multiple Myeloma (#149)
4:45 PM
Development of HER2-Specific Canine Chimeric Antigen Receptor-Natural Killer Cells for Canine Caner Immunotherapy (#150)
4:45 PM
Proinflammatory Cytokine IL-12 Drives Dynamic STAT4-dependent Changes in RNA Polymerase II Landscape Within Natural Killer Cells (#151)
4:45 PM
Seasonal variation of natural killer cell activity in health checkup subjects; real-world data (#152)
4:45 PM
Standard Treatment of Cervical Cancer Enhances Intestinal Dysbiosis and Correlates with NK Cell Exhaustion (#153)
4:45 PM
Systematic investigation of NK cell responses triggered by different activating receptors (#154)
4:45 PM
EphA2-Targeted CAR-NK Cell Therapy for Paediatric Sarcomas (#155)
4:45 PM
Genome-wide CRISPR Screening in Human Primary NK Cells Identify Countermeasures Against Immunosuppressive Environment (#156)
4:45 PM
Ex vivo expanded ieILC1-like NK cells induce significant tumor cell death and demonstrate metabolic flexibility under hypoxic conditions (#157)
4:45 PM
Co-Activating Tandem (CAT) CARs leverage heterogeneous activating signals to optimize NK cell functionality (#158)
4:45 PM
Arid1a governs NK cell development and function (#159)
4:45 PM
Effect of EVs Containing Different Alleles of MICA on NKG2D Modulation and Lytic Granule Mobilization in Natural Killer Cells. (#160)
4:45 PM
Identification of Tissue-Resident Adaptive NK Cells and Their Association With Reduced Mortality Across Diverse Solid Tumors (#161)
4:45 PM
CRISPR Screens Identify Targets Modulating Breast Cancer Vulnerabilities to NK Cells (#162)
4:45 PM
Natural killer cell TGF-β signaling influences pathological vascular remodeling in a mouse model of pulmonary hypertension (#163)
4:45 PM
Immunocytokines with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia (#189)
4:45 PM
Phenotypic and molecular modulations to NK cells during acute HIV infection (#190)
4:45 PM